Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb study of MenABCWY versus MenACWY booster vaccination in previously MenACWY-primed adolescents and adults
2019-004982-42Phase 3
- Sponsor
- GSK
- Start
- Feb 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in meningococcal disease comparing MenABCWY 2-dose schedule with MenACWY single-dose control (2 arms). Primary endpoints: Non-inferiority after first post-baseline vaccination and Non-inferiority after second MenABCWY vaccination.
02
Drugs
Meningococcal ABCWYmeningococcal ACWY conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2019-004982-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004982-42.